Derek Persons, MD, PhD

Derek Persons, MD, PhD

Associate Member, St. Jude Faculty

Departments

Hematology

Divisions

Experimental Hematology

Contact Information

Derek Persons, MD, PhD
Hematology
MS 341, Room D3007B
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: derek.persons@stjude.org
Phone: (901) 595-2146
FAX: (901) 595-2176

Education

MD - Duke University School of Medicine, Durham, North Carolina
PhD - Duke University Graduate School, Durham, North Carolina


Research Interests

Gene therapy approaches to the hemoglobin disorders of severe beta-thalassemia and sickle cell disease

The study of the zinc-finger transcription factor GATA-2


Selected Publications

Lebensburger JD, Howard T, Hu Y, Pestina TI, Gao G, Johnson M, Zakharenko SS, Ware RE, Tuomanen EI, Persons DA, Rosch JW. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood November 30, 2011.

Kasow KA, Morales-Tirado VM, Wichlan D, Shurtleff SA, Abraham A, Persons DA, Riberdy JM. Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX. Clin Immunol 141(2):169-76, 2011.

Hunter MJ, Zhao H, Tuschong LM, Bauer TR, Burkholder TH, Persons DA, Hickstein DD. Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters. Hum Gene Ther 22(6):689-96, 2011.

Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 117(15):3945-53, 2011.

Wilber A, Hargrove PW, Kim YS, Riberdy JM, Sankaran VG, Papanikolaou E, Georgomanoli M, Anagnou NP, Orkin SH, Nienhuis AW, Persons DA. Therapeutic levels of fetal hemoglobin in erythroid progeny of beta-thalassemic CD34(+) cells after lentiviral vector-mediated gene transfer. Blood 117(10):2817-26, 2011.

Persons DA, Baum C. Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol Ther 19(2):229-31, 2011.

Abraham A, Persons DA. Sickle cell disease: new treatment insights. Drugs Future 35(11):939-45, 2010.

Nasimuzzaman M, Khandros E, Wang X, Kong Y, Zhao H, Weiss D, Rivella S, Weiss MJ, Persons DA. Analysis of alpha hemoglobin stabilizing protein overexpression in murine β-thalassaemia. Am J Hematol 85(10):820-2, 2010.

Persons DA. Gene therapy: Targeting β-thalassaemia. Nature 467(7313):277-8, 2010.

Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica 95(9):1599-1603, 2010.

Soulas C, Donahue RE, Dunbar CE, Persons DA, Alvarez X, Williams KC. Genetically modified CD34+ hematopoietic stem cells contribute to turnover of brain perivascular macrophages in long-term repopulated primates. Am J Pathol May;174(5):1808-17, 2009.

Hanawa H, Yamamoto M, Zhao H, Shimada T, Persons DA. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther Apr;17(4):667-74, 2009.

Zhao H, Pestina TI, Nasimuzzaman M, Mehta P, Hargrove PW, Persons DA. Amelioration of murine {beta}-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both {gamma}-globin and the MGMT drug resistance gene. Blood, 2009.

Kim YJ, Kim YS, Larochelle A, Renaud G, Wolfsberg TG, Adler R, Donahue RE, Hematti P, Hong BK, Roayaei J, Akagi K, Riberdy JM, Nienhuis AW, Dunbar CE, Persons DA. Sustained high level polyclonal hematopoietic marking and transgene expression four years following autologous transplantation of rhesus macaques with SIV lentiviral vector transduced CD34+ cells. Blood Apr 1, 2009.

Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther  Feb;17(2):245-52, 2009.

Lebensburger J, Persons DA. Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell disease. Curr Opin Drug Discov Devel Mar;11(2):225-32, 2008.

Hargrove PW, Kepes S, Hanawa H, Obenauer J, Pei D, Cheng C, Gray, JT, Neale G, Persons DA. Globin lentiviral vector insertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells. Mol Ther, 2008.

Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, Nienhuis AW. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.enhancer/promoter. Blood, 2007.

Ryu B, Persons DA, Evans-Galea M, Gray JT, and Nienhuis AW. The influence of a chromatin insulator on interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol Dis, 2007.

Miller ML, Gao G, Pestina T, Persons D, Tuomanen E. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves PAF receptor. J Infect Dis Feb 15;195:581-4, 2007.

Zhang J, Randall MS, Loyd MR, Li W, Schweers RL, Persons DA, Rehg JE, Noguchi CT, Ihle JN, Ney PA. Role of erythropoietin receptor signaling in Friend virus-induced erythroblastosis and polycythemia. Blood 107:73-8, 2006.

Hanawa H, Persons DA, Nienhuis AW. Mobilization and mechanism of transcription of integrated self-inactivating (SIN) lentiviral vectors. J Virol 79:8410-21, 2005.

Dominici M, Merhdad T, KepesS, Allay ER, Boyd K, Ney PA, Horwitz E, Persons DA. Transgenic mice with pancellular enhanced green fluorescent protein expression in primitive hematopoietic cells and all blood cell progeny. Genesis 42:17-22, 2005.

Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, Holt IE, Eckfeldt CE, Sharma Y, Schmidt M, von Kalle C, Persons DA, Billings EM, Verfaillie CM, Nienhuis AW, Wolfsberg TG, Dunbar CE, Calmels B. Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells. PLoS Biol 2(12): Nov 23; e423, 2004.

Dominici M, Pritchard C, Garlits JE, Hofmann TJ, Persons DA, Horwitz EM. Hematopoietic and osteoblastic cells are derived from common marrow progenitor after bone marrow transplantation. Proc Natl Acad Sci USA, 2004.

Hanawa H, Hargfove PW, Kepes S, Srivastava DK, Nienhuis AW, Persons DA. Extended ß-globin locus control region elements promote consistent therapeutic expression of a γ-globin lentiviral vector in murine ß-thalassemia. Blood First Edition Paper, 2004.

Hanawa H, Hematti P, Keyvanfar K, Krouse A, Donahue RE, Kepes S, Dunbar CE, Persons DA, Nienhuis AW.  Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 103:4062-4069, 2004.

Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME, Donahue RE, Dunbar CE, Sorrentino BP. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques transplanted with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103:796-803, 2004.

Sawai N, Persons DA, Lu T, Sorrentino BP. Reduction in hematopoietic stem cell numbers with in vivo drug selection can be partially abrogated by HOXB4 expression. Molecular Therapy 8:376-385, 2003.

*Persons DA, Allay ER, Sawai N, Hargrove PW, Brent TP, Hanawa H, Nienhuis AW, Sorrentino BP. Successful treatment of murine beta-thalassemia using in vivo selection of genetically-modified, drug-resistant hematopoietic stem cells. Blood 102:6506-513, 2003. *Corresponding author

Persons DA. Update on Gene Therapy for the Hemoglobin Disorders. Current Opinion in Molecular Therapy 5:508-516, 2003.

Persons DA, Nienhuis AW. Gene therapy for the hemoglobin disorders. Current Hematology Reports 2: 348-351, 2003.

*Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine beta-thalassemia following lentivrial-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood  101:2175-2183, 2003. *Corresponding author

Hanawa H, Persons DA, Nienhuis AW. High level, erythroid lineage-directed gene expression using globin gene elements following lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. Human Gene Therapy 13:2007-2013, 2002.

Persons DA, Nienhuis AW. In vivo selection to improve gene therapy of hematopoietic disorders. Current Opinion in Molecular Therapy 4:491-498, 2002.

Hanawa H, Kelly PF, Nathwani AC, Persons DA, Carrington J, Hargrove P, Vanin EF, Nienhuis AW. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transducer primitive hematopoietic cells from human blood. Molecular Therapy 5:242-251, 2002.

Priller J, Glugel A, Wehner T, Boentert M, Haas C, Prinz M, Fernandez-Klett F, Prass K, Bechmann I, de Boer B, Frotscher M, Kreutzberg G, Persons DA, Dirnagl U. Targeting of gene-modified hematopoietic cells to the central nervous system: use of the green fluorescent protein uncovers microglial engraftment. Nature Medicine 7:1356-1361, 2001.

Priller J, Persons DA, Fernandez-Klett F, Kempermann G, Kreutzberg G, Dirnagl U. Neogenesis of cerebellar purkinge neurons from gene-marked bone marrow cells in vivo. Journal of Cell Biology 155:733-738, 2001.

*Persons DA, Allay ER, Sabatino DE, Kelly PF, Bodine DM, Nienhuis AW. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood 97:3275-3282, 2001. *Corresponding author

Persons DA, Nienhuis AW. Gene therapy for the hemoglobin disorders: past, present, and future. Proceedings of the National Academy of Sciences USA 97:5022-5024, 2000.

Donahue RE, Wersto RP, Allay JA, Agricola BA, Metzger ME, Nienhuis AW, Persons DA, Sorrentino BP. High levels of lymphoid expression of enhanced green fluorescent protein in non-human primates transplanted with cytokine mobilized peripheral blood CD34+ cells. Blood 95:445-452, 2000.

Persons DA, Paulson RF, Loyd MR, Herley MT, Bodner SM, Correll PH, Bernstein A, and Ney PA. Fv2 mediated susceptibility to Friend erythroleukemia virus is conferred by a truncated form of the STK/Ron receptor tyrosine kinase. Nature Genetics 23:159-165, 1999.

Persons DA, Allay JA, Allay ER, Ashmun RA, Orlic D, Cunningham JM, Jane SM, and Nienhuis AW. Enforced expression of GATA-2 transcriptional factor blocks normal hematopoiesis. Blood 93:488-499, 1999.

Last update: January 2012